Corticosteroids and human recombinant activated protein C for septic shock.
This article summarizes the current knowledge on the benefit/risk profile from the use of low-dose corticosteroids and activated protein C in treating septic shock. Physicians should consider using low-dose corticosteroids and drotrecogin alpha activated in the treatment of patients who have vasopressor-dependent septic shock with persistent signs of hypoperfusion, organ dysfunction, or hypotension. The optimal timing for initiating these treatments is from 6 to 24 hours from onset of shock. When patients are receiving these drugs, physicians should systematically screen for superinfection and serious bleeding events.
T1 T2 T3 T4 T5 T6
CHEMICAL CHEMICAL CHEMICAL GENE-Y GENE-Y GENE-Y
corticosteroids corticosteroids Corticosteroids activated protein C drotrecogin alpha human recombinant activated protein C